Century Therapeutics (IPSC) Net Margin (2022 - 2025)
Century Therapeutics (IPSC) posted quarterly Net Margin of 70.13% for Q1 2025, up 335224.0% year-over-year from N/an in Q1 2024, and up 108.2% quarter-over-quarter from 854.85% in Q4 2024.
Powered by 
Analysis
Century Therapeutics (IPSC) Net Margin (2022 - 2025) Analysis & Trends
Century Therapeutics (IPSC) has reported Net Margin for 4 consecutive years, with 70.13% the latest figure, recorded in Q1 2025.
- In Q1 2025, Net Margin rose 335224.0% year-over-year to 70.13%; the TTM figure through Dec 2025 stood at 0.05% (up 191458.0% YoY), while the FY2025 annual figure was 1.9%, up 191669.0% from the prior year.
- Net Margin climbed to 70.13% in Q1 2025 per IPSC's latest filing, from 854.85% in the prior quarter.
- Across five years, Net Margin topped out at 70.13% in Q1 2025 and bottomed at 33627.27% in Q2 2023.
- Historically, Net Margin has averaged 7503.45% across 4 years, with a median of 3545.65% in 2022.
- Annual changes were most pronounced in 2023 — Net Margin slumped 3140750 bps — and 2024, when it jumped 2957967 bps.
- Century Therapeutics' Net Margin stood at 6081.0% in 2022, then plunged by 142 bps to 14700.75% in 2023, then surged by 94 bps to 854.85% in 2024, then jumped by 108 bps to 70.13% in 2025.
- Business Quant data shows IPSC's Net Margin at 70.13% in Q1 2025, 854.85% in Q4 2024, and 3947.66% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 70.13% |
| Dec 31, 2024 | -194.82% |
| Sep 30, 2024 | -3,947.66% |
| Jun 30, 2024 | -4,047.60% |
| Mar 31, 2024 | -3,282.11% |
| Dec 31, 2023 | -14,701.87% |
| Sep 30, 2023 | -22,108.11% |
| Jun 30, 2023 | -33,627.27% |
| Mar 31, 2023 | -1,817.67% |
| Dec 31, 2022 | -6,081.00% |
| Sep 30, 2022 | -1,382.60% |
| Jun 30, 2022 | -2,219.77% |
| Mar 31, 2022 | -3,545.65% |